Published in J Heart Lung Transplant on May 02, 2012
Is it time to give up with calcineurin inhibitors in kidney transplantation? World J Transplant (2013) 0.86
IgM-Enriched Human Intravenous Immunoglobulin-Based Treatment of Patients With Early Donor Specific Anti-HLA Antibodies After Lung Transplantation. Transplantation (2016) 0.76
Impact of endoscopic versus open saphenous vein harvest techniques on outcomes after coronary artery bypass grafting. Ann Thorac Surg (2010) 3.71
Frail patients are at increased risk for mortality and prolonged institutional care after cardiac surgery. Circulation (2010) 2.31
Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl (2006) 2.13
Outcomes after aortic and mitral valve replacement surgery in Canada: 1994/95 to 1999/2000. Can J Cardiol (2004) 2.11
Identifying patients at risk of intraoperative and postoperative transfusion in isolated CABG: toward selective conservation strategies. Ann Thorac Surg (2004) 2.02
Coronary bypass surgery performed off pump does not result in lower in-hospital morbidity than coronary artery bypass grafting performed on pump. Circulation (2004) 1.95
Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl (2007) 1.76
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol (2002) 1.71
Clopidogrel increases blood transfusion and hemorrhagic complications in patients undergoing cardiac surgery. Ann Thorac Surg (2010) 1.68
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl (2006) 1.56
The intraaortic balloon pump in cardiac surgery. Ann Thorac Surg (2002) 1.29
Use of valve surgery in Canada. Can J Cardiol (2004) 1.28
Is it safe to train residents to perform cardiac surgery? Ann Thorac Surg (2002) 1.13
A multicenter comparison of intraaortic balloon pump utilization in isolated coronary artery bypass graft surgery. Ann Thorac Surg (2003) 1.10
Training residents in mitral valve surgery. Ann Thorac Surg (2004) 1.08
Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant (2003) 1.04
Infectious endocarditis of a Chiari network. Ann Thorac Surg (2003) 1.01
Reduction in postoperative adhesion formation and re-formation after an abdominal operation with the use of N, O - carboxymethyl chitosan. Surgery (2004) 1.00
Conversion to on pump from OPCAB is associated with increased mortality: results from a randomized controlled trial. Eur J Cardiothorac Surg (2005) 0.99
Outcomes after coronary artery bypass graft surgery in Canada: 1992/93 to 2000/01. Can J Cardiol (2003) 0.96
Neutrophil mediated smooth muscle cell loss precedes allograft vasculopathy. J Cardiothorac Surg (2010) 0.96
Myocardial fibrosis in response to Angiotensin II is preceded by the recruitment of mesenchymal progenitor cells. Lab Invest (2010) 0.94
Echinacea-induced macrophage activation. Immunopharmacol Immunotoxicol (2008) 0.94
The Canadian Society of Cardiac Surgeons perspective on the cardiac surgery workforce in Canada. Can J Cardiol (2012) 0.92
The association between prior percutaneous coronary intervention and short-term outcomes after coronary artery bypass grafting. Am Heart J (2005) 0.92
The effect of place of residence on access to invasive cardiac services following acute myocardial infarction. Can J Cardiol (2009) 0.92
Regulation and role of connective tissue growth factor in AngII-induced myocardial fibrosis. Am J Pathol (2012) 0.91
Long-term results of heart operations performed by surgeons-in-training. Circulation (2008) 0.90
Mitral insufficiency and morbidity and mortality in left ventricular dysfunction. Can J Cardiol (2007) 0.90
Contribution of B cells and antibody to cardiac allograft vasculopathy. Transplantation (2009) 0.88
The preoperative intraaortic balloon pump in coronary bypass surgery: a lack of evidence of effectiveness. Am Heart J (2005) 0.87
Hemodynamic performance of the St. Jude Medical Epic Supra aortic stented valve. J Heart Valve Dis (2011) 0.85
Fibroblast progenitor cells are recruited into the myocardium prior to the development of myocardial fibrosis. Int J Exp Pathol (2012) 0.85
IFN-gamma and Fas/FasL pathways cooperate to induce medial cell loss and neointimal lesion formation in allograft vasculopathy. Transpl Immunol (2009) 0.84
Complete revascularization is compromised in off-pump coronary artery bypass grafting. J Thorac Cardiovasc Surg (2012) 0.84
CD8(+) T cells mediate aortic allograft vasculopathy under conditions of calcineurin immunosuppression: role of IFN-gamma and CTL mediators. Transpl Immunol (2008) 0.83
Aortic allograft vasculopathy is mediated by CD8(+) T cells in Cyclosporin A immunosuppressed mice. Transpl Immunol (2005) 0.83
The dome of the left atrium: an alternative approach for mitral valve repair. Eur J Cardiothorac Surg (2003) 0.83
Treatment with activated protein C (aPC) is protective during the development of myocardial fibrosis: an angiotensin II infusion model in mice. PLoS One (2012) 0.82
CD8+ gammadelta T regulatory cells mediate kidney allograft prolongation after oral exposure to alloantigen. Transpl Int (2008) 0.81
Antimycobacterial screening of traditional medicinal plants using the microplate resazurin assay. Can J Microbiol (2010) 0.81
Immunologic targets in the etiology of allograft vasculopathy: endothelium versus media. Transpl Immunol (2008) 0.80
Early innate immune events induced by prolonged cold ischemia exacerbate allograft vasculopathy. J Cardiothorac Surg (2011) 0.80
CD8+ T cells mediate aortic allograft vasculopathy by direct killing and an interferon-gamma-dependent indirect pathway. Cardiovasc Res (2005) 0.79
Preoperative cardiovascular risk factor control in elective coronary artery bypass graft patients: a failure of present management. Can J Cardiol (2002) 0.79
The impact of sequential grafting on clinical outcomes following coronary artery bypass grafting. Eur J Cardiothorac Surg (2010) 0.79
The composition of ectopic lymphoid structures suggests involvement of a local immune response in cardiac allograft vasculopathy. J Heart Lung Transplant (2014) 0.78
Impact of donor benign intimal thickening on cardiac allograft vasculopathy. J Heart Lung Transplant (2013) 0.78
Use of a sulfated chitosan derivative to reduce bladder inflammation in the rat. Urology (2007) 0.78
Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. Transplantation (2009) 0.78
Reduction in postsurgical adhesion formation after cardiac surgery in a rabbit model using N,O-carboxymethyl chitosan to block cell adherence. J Thorac Cardiovasc Surg (2008) 0.77
Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation (2007) 0.77
Antibody therapy can enhance AngiotensinII-induced myocardial fibrosis. Fibrogenesis Tissue Repair (2014) 0.77
Recipient cells form the proliferative lesion in the rat heterotopic tracheal allograft model of obliterative airway disease. J Heart Lung Transplant (2003) 0.76
Contribution of pre-existing vascular disease to allograft vasculopathy in a murine model. Transpl Immunol (2009) 0.76
A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation. J Transplant (2012) 0.75
Determinants of percutaneous coronary intervention vs coronary artery bypass grafting: an interprovincial comparison. Can J Cardiol (2013) 0.75
Reduction in postsurgical adhesion formation after cardiac surgery by application of N,O-carboxymethyl chitosan. J Thorac Cardiovasc Surg (2010) 0.75
Immunostimulant properties of Heracleum maximum Bartr. J Ethnopharmacol (2006) 0.75
Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A. Int J Oncol (2004) 0.75
The year in review--2004. Clin Transpl (2004) 0.75
Impairment of recipient cytolytic activity attenuates allograft vasculopathy. Transpl Immunol (2005) 0.75